ENDOPREDICT

Protein biomarker for the prediction of response to endocrine treatment in breast cancer patients

 Coordinatore ROYAL COLLEGE OF SURGEONS IN IRELAND 

 Organization address address: Saint Stephen's Green 123
city: DUBLIN
postcode: 2

contact info
Titolo: Prof.
Nome: Leonie
Cognome: Young
Email: send email
Telefono: +353 1 4028576

 Nazionalità Coordinatore Ireland [IE]
 Totale costo 570˙313 €
 EC contributo 570˙313 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2012-IAPP
 Funding Scheme MC-IAPP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-02-01   -   2017-01-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    ROYAL COLLEGE OF SURGEONS IN IRELAND

 Organization address address: Saint Stephen's Green 123
city: DUBLIN
postcode: 2

contact info
Titolo: Prof.
Nome: Leonie
Cognome: Young
Email: send email
Telefono: +353 1 4028576

IE (DUBLIN) coordinator 390˙695.03
2    ALMAC DIAGNOSTICS LIMITED

 Organization address address: SEAGOE INDUSTRIAL ESTATE 20
city: CRAIGAVON
postcode: BT63 5QD

contact info
Titolo: Dr.
Nome: Karen
Cognome: Keating
Email: send email
Telefono: +44 28 38395982

UK (CRAIGAVON) participant 179˙618.56

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

predictive    hoxc    breast    treatment    cancer    patients    endocrine   

 Obiettivo del progetto (Objective)

'Classical pathologic parameters have been used to inform adjuvant clinical treatment choices for early breast cancer patients. There remain a significant number of patients however, who despite a reportedly favourable prognostic profile, experience metastatic disease. Elucidation of the mechanisms of tumour adaptability and the identification of predictive markers of early recurrence is the basis of personalized medicine. Work from our group has established the developmental protein HOXC11 as a powerful predictor of resistance to endocrine treatment in breast cancer patients .The aim of this project is to establish a joint industry-academia partnership to produce a commercially viable and clinically validated predictive assay/kit which based on the use of HOXC11 as a predictive biomarker of poor response to endocrine treatment in breast cancer patients.'

Altri progetti dello stesso programma (FP7-PEOPLE)

PROTEPROBE (2013)

Electrically Controlled Protein Conformation on 3D Tissue Scaffolds

Read More  

SFAP2 (2010)

Structural and Functional Analysis of Photosystem 2 from Nicotiana tabacum

Read More  

NANODIA (2011)

Nano-diamond building blocks for micro-device applications

Read More